The people who steer the MMRF are deeply committed to curing cancer now. They have been instrumental in establishing our culture of speed, innovation and results, and continue to help accelerate the development of new and better treatments and cures. Meet them here.
There is room for innovation and efficiency to accelerate cancer research. That’s why Kathy Giusti believes in transforming how new treatments are developed across all cancers. By putting patients at the center of everything.
As Co-Chair at the Harvard Business School Kraft Precision Medicine Accelerator, Kathy is working with disruptive leaders across the cancer ecosystem to revolutionize and accelerate business models in precision medicine.
As Founder of the Multiple Myeloma Research Foundation (MMRF) and a patient herself, Kathy knows firsthand how to bring a community together to drive toward cures. It was there, at the MMRF, that Kathy first drew on her extensive experience in the pharmaceutical industry to build collaborative models and aligned incentives, always with a focus on the patient.
Founder and Chief Mission Officer
Henry and Allison McCance Family Senior Fellow of Business Administration
Faculty Co-Chair, HBS Kraft Precision Medicine Accelerator
Kathy Giusti, a multiple myeloma patient, is the Founder of the Multiple Myeloma Research Foundation (MMRF) and the Multiple Myeloma Research Consortium (MMRC). She is the Henry & Allison McCance Family Senior Fellow at Harvard Business School, where she serves as Faculty Co-Chair of HBS Kraft Precision Medicine Accelerator, a $20M program endowed by Robert Kraft and the Kraft Family Foundation. She currently serves on the MMRF Board of Directors. Giusti has more than two decades of experience in the pharmaceutical industry, previously holding senior positions at G.D. Searle and Merck.
Since founding the MMRF in 1998, Giusti has become a widely respected leader in establishing innovative, collaborative research models in the areas of tissue banking, genomics, and clinical trials. These models are dramatically accelerating the pace at which lifesaving treatments are brought to patients and are building an end-to-end solution in precision medicine. Today, Giusti is recognized as a pioneer of precision medicine, a champion of open-access data sharing, and a strong advocate for patient engagement.
In 2016, Giusti was named Faculty Co-Chair of the Harvard Business School (HBS) Kraft Precision Medicine Accelerator. Under Giusti’s leadership, the HBS Kraft Precision Medicine Accelerator convenes best-in-class leaders from science, business and technology to identify and solve challenges slowing the advancement of precision medicine. The HBS Kraft PM Accelerator disseminates best practices and models to overcome these challenges, and, ultimately, enables faster adoption of high-impact innovations.
Giusti’s has earned several prestigious awards and recognitions, including being named 1 of 3 Top Business Leaders Disrupting Medicine by Fortune Magazine and #19 on Fortune’s World’s 50 Greatest Leaders list. Giusti was also named one of the world’s 100 Most Influential People by TIME magazine. In 2017, she received PRIMO’s Exceptional Women in Oncology award. In addition, she received the Open Science Champion of Change award by the White House and has been honored with the American Association for Cancer Research Centennial Medal for Distinguished Public Service and the Healthcare Businesswomen’s Association’s Woman of the Year Award.
Giusti served on President Obama’s 2015 Precision Medicine Initiative Working Group and continues to act as an active advisor to the Obama PMI (“All of Us”) and Vice President Biden’s Cancer Moonshot program. She currently is a member of the Harvard Business School (HBS) Health Advisory Board and has previously served on the President’s Council of Advisors on Science and Technology (PCAST), National Cancer Advisory Board (NCAB), and the National Cancer Policy Board (NCBP).
Giusti has been featured on the Today Show, NBC Nightly News, CBS Evening News, Fox News, CNN, and Bloomberg. Her efforts have also been profiled by Fortune, The Wall Street Journal, Harvard Business Review, The New York Times, Forbes, The New Yorker, WIRED, and Fast Company.
Giusti received her MBA in general management from Harvard Business School. She holds an honorary Doctorate from the University of Vermont.
President and Chief Executive Officer
Paul Giusti is the President and Chief Executive Officer of the Multiple Myeloma Research Foundation (MMRF), a world-renown cancer-research organization. Prior to the MMRF, Mr. Giusti worked as a Chief Executive Officer, leader, executive and entrepreneur for over 30 years; he has founded, managed and led a variety of businesses. Early in his career, Mr. Giusti worked as an executive for GE where he held a number of management positions with a wide range of responsibilities.
Mr. Giusti has worked closely with the MMRF since its founding in 1998. In addition to chairing the successful $100 million capital campaign, he has served as a consultant for a number of foundation projects, led several MMRF outreach efforts and spoken on behalf of the MMRF.
Mr. Giusti holds a Bachelor of Science degree from the Colorado School of Mines and an MBA from Harvard University.
Executive Partner and Founder
Chairman of the Board
Mike has 28 years of operating and management experience, most recently at Quintiles an Executive Vice President. In this role, Mike was responsible for Quintiles’ global operations in Health Engagement and Communications, Legal and Risk Management, Real Estate and Facilities, Human Resources as well as Security. He was also the Chairman of the company’s European, Middle East, Africa and Latin American management board, in which he was accountable for the organic and inorganic growth strategies of the regions. Mike joined Quintiles in July of 2003 following 10 years at Charles Schwab Corp., where he was Senior Vice President of Human Resources for the company’s global retail and internet organisations. Mike sits on the boards of Oxford Cancer Biomarkers Ltd., HUYA Bioscience International and the Multiple Myeloma Research Foundation. He holds a bachelor’s degree in Behavioural Sciences from The Ohio State University.
Lori Tauber Marcus
Vice Chairman of the Board
Lori Marcus is an independent board director and keynote speaker. She is currently serving in the role of Vice Chairman of the MMRF board. Lori is also the Chairman of the board of DNA Diagnostics Center, a growing leader in private DNA testing services, where she guides overall strategy and governance for corporate growth. Additionally, she is an independent Board Director for SHARE, a 40-year-old survivor-led organization based in New York City that provides support, information, and resources to women affected by breast and ovarian cancers. Lori also currently serves on the CMO advisory board for VentureBeat and is a board advisor to Carrington Farms.
Most recently, Ms. Marcus served as Interim Global Chief Marketing Officer for Peloton Interactive, Inc., a private equity and venture capital backed home fitness innovator, At Peloton, Lori drove business growth with strategy, brand marketing, communications, PR, social/digital media, consumer insights, data analytics, creative services, and community engagement. Prior, Lori was Chief Global Brand and Product Officer at Keurig Green Mountain. With more than 30 years of broad-based marketing and general management experience, Lori was responsible for global brand and product management for the Keurig system of innovative brewers and beverages. During her tenure at Keurig Green Mountain, she also led the company’s global marketing efforts and all aspects of e-commerce, digital/social media, marketing insights, and graphic design. Lori was also formerly Chief Marketing Officer of The Children’s Place Retail Stores and SVP Marketing at PepsiCo.
Lori is a graduate of the Wharton School, University of Pennsylvania.
Kenneth Anderson, MD
Dr. Anderson graduated from Johns Hopkins Medical School. He trained in internal medicine at Johns Hopkins Hospital and completed hematology, medical oncology, and tumor immunology training at the Dana-Farber Cancer Institute. Dr. Anderson is the Kraft Family Professor of Medicine at Harvard Medical School and serves as Chief of the Division of Hematologic Neoplasia, Director of the Jerome Lipper Multiple Myeloma Center, and Vice Chair of the Joint Program in Transfusion Medicine at the Dana-Farber Cancer Institute. He received the Waldenstrom’s Award in 2003 for his translational research directed to the development of novel therapeutics targeting the myeloma cell in its microenvironment and is a Doris Duke Distinguished Clinical Research Scientist. In addition to serving on the Board of Directors of the MMRF, Dr. Anderson serves as Chairman of the MMRF’s Scientific Advisory Committee, Chairman of the Multiple Myeloma Research Consortium, and Chairman of the National Comprehensive Cancer Network’s Multiple Myeloma Clinical Practice Guidelines Committee.
Karen E. Andrews
Senior Vice President and General Counsel
Karen E. Andrews is currently SVP and General Counsel for the March of Dimes. Previously Karen was the General Counsel and Corporate Secretary of BBDO Worldwide, Inc. where she was responsible for the management of the legal activities of over 150 individual operating units throughout the world. Prior to joining BBDO Worldwide, Ms. Andrews was Associate General Counsel and Director of Television Business Affairs at Time Inc. Ms. Andrews began her career in law as a Litigation Associate at the New York law firm of Weil, Gotshal & Manges where she specialized in Entertainment Litigation. Ms. Andrews graduated cum laude from the University of Vermont with a Bachelor of Science degree in biology and earned her law degree, cum laude, from Temple School of Law. Ms. Andrews is a member of the American Bar Association and the New York State Bar Association. In 1998, Ms. Andrews co-founded the Multiple Myeloma Research Foundation with Kathy Giusti.v
Tom was appointed President of SAC Capital in July 2008. He joined SAC in October 1999 as Chief Operating Officer. Prior to joining SAC, Tom was President of Investment Management Services, Inc (“IMS”) from 1996 to 1999. He joined Moore Capital /IMS in 1993 and served as its Director of Trading Operations and then Vice President until IMS split off from Moore in 1995. Tom joined Moore Capital /IMS from Goldman Sachs Trust Company, where he was a Vice President with responsibilities for daily operations, technology, and client services. From 1986 to 1993, Tom was in the operations and equity divisions of Goldman, Sachs & Co., becoming Vice President in 1991. He retired from SAC December 2014.
Corporate and Business Law, Real Estate Law
Gilmore joined ESPN in August of 1996 as a college football analyst. He currently works on ESPN/ABC Saturday telecast with Mark Jones and Quint Kessenich and contributes to studio shows including College Football Live, Outside the Lines and SportsCenter. He previously served as an ESPN studio analyst and a contributor to ESPN.com and ESPN The Magazine.
Prior to joining ESPN, Gilmore worked as an analyst with Prime Sports Network in California (1993-95), covering Pac-10 football, along with SportsChannel Bay Area from 1991-93 and the Pacific Sports Network in 1990. He was nominated for an Emmy Award in 1994 for live sports coverage of Pac-10 football.
A 1982 Stanford University graduate with a degree in English, Gilmore was a defensive back under coaches Bill Walsh, Rod Dowhower and Paul Wiggin, and also played baseball for Stanford.
Following graduation from Stanford, he earned his law degree from the University of California at Berkeley (Boalt Hall) in 1986, and was admitted to the California State Bar the same year. He began his law career in Los Angeles with the firm of Manatt Phelps & Phillips, LLP before returning to the Bay Area in 1988. He became a partner in the San Francisco business law firm Greene Radovsky Maloney & Share LLP in 1993. In 1997, he joined the Palo Alto, CA business law firm of Doty, Barlow, Britt & Thieman LLP. Rodney specializes in transactional law with an emphasis on business formation and planning, mergers and acquisitions, and commercial transactions. He also has extensive experience in commercial real estate matters, including sales and acquisitions, financings and leases.
Gilmore is a longtime volunteer for Stanford. He is a member and former officer of two entities sponsored by the Stanford Alumni Association. He previously served as chairman of the Stanford Athletic Board and as a member of the Board of Directors of the Stanford Alumni Association. He is also an active member of several Bar Associations and several local community organizations.
An Oakland, CA native, Gilmore is a member of the Oakland Babe Ruth Baseball Hall of Fame. He lives in the Bay Area with his wife, Marie, the former Mayor of Alameda, CA, and has two adult children (Anthony and Nicole).
David L. Lucchino
Co-Founder, President and Chief Executive Officer
David is the Co-founder, President and Chief Executive Officer of Frequency Therapeutics. He has over 20 years of entrepreneurial experience and has played an integral role in launching, building and operating many successful companies in the life sciences and other innovation sectors. Previously, David was the President and Chief Executive Officer of Entrega Bio, a PureTech Health company developing an innovative capsule technology to make injectable substances available orally.
David’s first MIT-based startup was Semprus BioSciences, a biomedical company that went from business concept, to FDA 510(k) clearance and CE Mark approval, to major acquisition in five years. Semprus won the MIT $100K Entrepreneurial Competition for its business plan to develop a novel platform technology for reducing complications associated with long-term medical device implants, such as thrombosis and microbial adhesion. David subsequently led Semprus’ closing on several large financings before the company was acquired by Teleflex in 2012. Prior to Semprus, David was a Senior Executive at the leading venture capital firm, Polaris Partners, where he was responsible for deal-sourcing and originating and the execution of Polaris’ investment in Athletes Performance, a leading training facility for NFL, MLB, NHL and NBA professional athletes.
David launched his career in the life sciences by co-founding LaunchCyte, an investment firm specialized in commercializing biomedical intellectual property, and was instrumental in launching six companies from Carnegie-Mellon University and the University of Pennsylvania, among others. David currently serves as Vice Chairman of the Board of Directors of MassBio. He serves as a trustee and Chair of the Audit Committee of Mt. Auburn Hospital, a Harvard Medical School facility, and holds a Board position with the Multiple Myeloma Research Foundation. David is on the advisory council for the National Outdoor Leadership School (NOLS) where he was part of an expedition that summited Denali, North America’s high point. David earned an MBA at the MIT Sloan School of Management as an Alfred P. Sloan Fellow, an M.S. from Syracuse University and a B.A. from Denison University.
Dana LaForge is a Partner at Brera Capital Partners, a private equity fund, and the Founder and Managing Partner of Colonnade Financial Group, a private equity services firm. Prior to Brera and Colonnade, Dana was head of Financial Institutions Investment Banking and Chief of Staff of Banking and Capital Markets at Deutsche Bank and its predecessor companies. Earlier in his career, he was a bond trader and founded the Mortgage Finance Group. Dana has served on numerous portfolio company boards and is the Chairman of GAB Robins NA. He was one of the earliest Directors of the Multiple Myeloma Research Foundation joining the Board in 1999 and helping guide the Foundation from start up through today serving as the organization’s only Chairman since being elected in 2003. Dana earned a BS from Washington and Lee University and an MBA from Harvard Business School. He lives in New York City with his wife, Kathleen McCabe and their two daughters.
Susan Marvin serves as Vice Chair of The Marvin Companies and is a member of the company’s Executive Steering Committee. She has been part of the third generation management team and is one of 14 third and fourth generation Marvin family members operating the company today.
Active in both profit and nonprofit boards, Susan serves on The Marvin Companies Board of Directors, M. A. Mortenson Company Board of Directors, the Harvard University Joint Center for Housing Studies Policy Advisory Board Executive Committee, the National Association of Manufacturers Board of Directors, the Minneapolis Institute of Art Board of Trustees, and the University of Minnesota Foundation Board of Trustees. She is a member of the World Presidents’ Organization (WPO).
Prior to her current role, Susan was President of Marvin Windows and Doors and oversaw the fenestration business. She joined the firm in 1981 as Marketing Manager, in 1985 was V.P. of Sales and Marketing, and was appointed President in 1995 and served in that position until 2015.
Susan is a 1979 graduate of the University of Minnesota where she earned an undergraduate degree in Journalism. A native of Warroad, Minnesota, Susan now lives in both Warroad and Minneapolis with her husband, Keith Schwartzwald.
Mr. McDougall is Partner at PricewaterhouseCoopers Health Sciences Practice, where he provides services to academic medical centers, bioscience companies, pharmaceutical companies, research universities, colleges, health systems, and other research organizations. His practice provides a broad range of research business and compliance services, including strategic and business planning, financial analysis, research compliance, clinical research operations improvement, and information systems implementation services. In addition, his practice provides support services to the entire research continuum, from grant-funded basic science research, to translational research and clinical trials, including a dedicated group focusing on Clinical Research Consulting services.
William S. McKiernan
Former Chair and CEO
William McKiernan is the Chairman and Chief Executive Officer of CyberSource Corporation. Prior to founding CyberSource, Mr. McKiernan was President and Chief Operating Officer of McAfee Associates, now Network Associates; Mr. McKiernan held this position during the company’s initial public offering. Before joining McAfee, Mr. McKiernan was Vice President of Princeton Venture Research, Inc. and held management positions at ROLM/IBM. In addition to serving on the Board of Directors of the MMRF, Mr. McKiernan is the West Coast Chairman of the Boston College Technology Council. Mr. McKiernan holds a Bachelor of Science from Boston College and an MBA from Harvard Business School.
David R. Parkinson, MD
Chairman of the Clinical Advisory Board
From 2007 until 2012, Dr. Parkinson served as President and CEO of Nodality, a South San Francisco-based venture-financed biotechnology company developing technologies to enable personalized medicine and more efficient drug development in cancer and autoimmune diseases. Before joining Nodality, Dr. Parkinson was Senior Vice President, Oncology R&D, at Biogen Idec, overseeing oncology discovery research efforts and the development of the oncology pipeline. Previously he had served tenures as Vice President and Head of the Oncology Therapeutic Area at Amgen and Vice President and Head of Global Clinical Oncology Development at Novartis. During his tenures at Amgen and Novartis, Dr. Parkinson was responsible for clinical development activities leading to a series of successful global drug registrations for important cancer therapeutics, including Gleevec®, Femara®, Zometa®, Kepivance®, and Vectibix®. He received his M.D. from the University of Toronto Faculty of Medicine in 1977, with Internal Medicine and Hematology/Oncology training at McGill University and at New England Medical Center. Dr. Parkinson has authored more than 100 peer-reviewed scientific papers, and is a past Chairman of the Food & Drug Administration (FDA) Biologics Advisory Committee as well as a recipient of the FDA’s Cody Medal.
Marie E. Pinizzotto, M.D., MBA
President and CEO
Marie E. Pinizzotto, M.D.,MBA is currently the President and CEO of the Carol A. Ammon Foundation, a foundation focused on health care and education . Prior to running the foundation she was president of Drug Safety Solutions, L.L.C., a Pharmacovigilance and Risk Management consulting company whose main focus was narcotics and other high-risk drugs. Dr. Pinizzotto also worked at Endo Pharmaceuticals Inc. where she was Senior Director of the Global Safety and Pharmacovigilance department. In this role she was responsible for pharmacovigilance of all Endo products, marketed and investigational. Marie was also responsible for the safety components in following disciplines; Clinical Research, Medical Affairs and Clinical Education and Development. she led the Risk Management Team and was responsible for the creation and implementation of Endo’s risk management programs.
Before working at Endo, she was a Senior Director of Report Evaluation and Safety Surviellance for the Women’s Health Division and Consumer Products at Wyeth she was responsible for drug safety and pharmacovigilnce of Wyeth products.
Dr. Pinizzotto received her B.S in Chemistry, magna cum laude, from the University of Pittsburgh, Pittsburgh Pennsylvania and her medical degree from Jefferson Medical College in Philadelphia. ( Now Sidney Kimell Collge of Medicine.) She completed her residency at The Medical Center of Delaware,( now Christiana Care) where she practiced obstetrics and gynecology.. Most recently, Dr. Pinizzotto earned her MBA at the University of Delaware.
Currently Dr. Pinizzotto is the named Chair of Obstetrics and Gynecology at Christiana Care Hospital, Newark, Delaware, and is also a trustee of the hospital. She is member of the finance committee and was a member of the Quality and Safety Committee. In addition, she is board member at Eisenhower Medical Center, Rancho Mirage, California, and also sits on the quality improvement committee. At Eisenhower she is named Chair, The Marie E. Pinizzotto, MD Chair of Academic Affairs, Dr Pinizzotto is also a director, The Carol A. Ammon Foundation and The Multiple Myeloma Research Foundation. In addition she participates on the following advisory boards: Scientific Steering Committee on Personalized Medicine for the Multiple Myeloma Research Foundation ; The Presidents Leadership Council of the University of Delaware, the Presidents Leadership Council at Jefferson Medical College; the Advisory Board of Myeloma Institute at the University of Arkansas Medical System. In addition, she is one of the founding members of the MGH Leadership Council for Psychiatry at Massachusetts General.
Michael Reinert is a leading music industry attorney who most recently served as Executive Vice President of Business & Legal Affairs for the Universal Motown Republic Group, a division of UMG Recordings, Inc. In that position, he had the pleasure of working with great talent such as Stevie Wonder, Elton John, Taylor Swift, Amy Winehouse, Lil Wayne, Nelly, Jack Johnson and many other platinum selling acts. Prior to joining Universal ten years ago, Michael was the Vice President of Business & Legal Affairs for PolyGram Records, handling those duties for the legendary Verve Records label and Mercury Nashville Records where he worked with the likes of Herbie Hancock and Shania Twain. Michael started his career in private practice representing many artists, producers and writers before joining the corporate ranks. Michael was an Adjunct Professor of Law at his alma mater, The Benjamin Cardozo School of Law of Yeshiva University, for ten years teaching Contract Drafting and Negotiation in the Music Industry. He has been a contributing editor to the Practicing Law Institute volumes on the same subject and continues to lecture at various schools and seminars around the country. He currently serves as the Chairman of the Entertainment Law Initiative of the Grammy Foundation, a division of the National Academy of Recording Arts and Sciences, which focuses on legal education programs for aspiring entertainment attorneys. Michael attended the Horace Mann School for Boys in Riverdale and Tulane University in New Orleans, a place he considers his second home. He lives in Manhattan with his wife of 30 years, Karen. They have a daughter and two beautiful grandchildren.
Former CEO and Founder
Rodger Riney grew up in Kirkwood, Missouri, and graduated from the University of Missouri with a Civil Engineering degree and an MBA. In 1969, he joined Edward D. Jones & Co. in Saint Louis and later became a partner. In 1980, he left to enter the relatively new discount brokerage industry by starting Scottrade. Over the years, Scottrade evolved into an online brokerage and bank supporting its 3 million clients through 500 branch offices nationwide. In the fall of 2015, Rodger was diagnosed with multiple myeloma and in late 2017, Scottrade was sold to TD Ameritrade.
Steven Shak, MD
Co-Founder, Chief Scientific Officer
Dedicated to optimizing cancer treatment outcomes and bringing the patient voice into product development, Steve Shak, M.D. has served as the Co-Founder, Chief Scientific Officer since 2012 and was the Chief Medical Officer from 2000 – 2013. Under Steve’s leadership Genomic Health used innovative molecular diagnostic methods and rigorous clinical studies to develop the Oncotype DX® breast cancer and colon cancer assays and has maintained an 80% product development success rate. Steve has been a leader in personalized medicine for more than two decades. Prior to co-founding Genomic Health in 2000, Steve served for 14 years in various roles in Discovery Research and Medical Affairs at Genentech, Inc., a biotechnology company dedicated to using human genetic information to discover, develop, manufacture and commercialize medicines to treat patients with serious or life-threatening medical conditions. Steve led the clinical team that gained approval for Herceptin®, a targeted biologic treatment for breast cancer. He also initiated the cancer clinical trials of the anti-angiogenesis agent, Avastin®. In addition, Steve discovered Pulmozyme®, a mucus-dissolving enzyme that is approved worldwide for the treatment of the genetic disease cystic fibrosis. Prior to joining Genentech, Steve was an Assistant Professor of Medicine and Pharmacology at New York University School of Medicine. Steve holds a Bachelor of Arts degree in Chemistry from Amherst College and an M.D. from New York University School of Medicine, and completed his post-doctoral training at University of California, San Francisco.
Chief Financial Officer
Meryl Zausner has over 35 years of management experience across the pharmaceutical and consumer products industries. Meryl was instrumental in creating the blueprint for the successful Novartis Oncology Business Unit and engineering the launch of the first Novartis shared services organization. A recognized developer of diverse talent, The Healthcare Businesswomen Association honored Meryl with its prestigious Woman of Year Award.
For much of her corporate career, Meryl worked at Novartis AG, the Swiss pharmaceuticals company, in roles of increasing responsibility across diversified businesses. From April 2012 through 2014, Meryl was Chief Financial and Administrative Officer of Novartis Pharmaceuticals Corporation in the US, and a member of the Pharmaceutical Executive Committee and Global Finance Leadership Team. While in this role, Meryl also resumed responsibility as Chief Financial Officer and Executive Vice President of Novartis Corporation in the US.
Acknowledging her strong leadership and broad achievements, Novartis selected Meryl to train and serve as a certified Executive Coach to senior executives, a position she held from May 2015 until her retirement at the end of June 2017. She has a BS in Economics and Accounting from the University at Albany and her CPA.
Meryl is a Board member and Chair of the Audit Committee of the Multiple Myeloma Research Foundation, and Board member of Deirdre’s House, an advocacy center for children who are victims of abuse or neglect. Former board positions include HBA Advisory Board, PhRMA Audit and Finance Subcommittee member, and the T.J. Martell Foundation. PharmaVoice magazine recognized Meryl among its Most Inspiring, and she received Gilda Club’s Red Door Honoree. Meryl resides with her husband in Naples, Florida and Long Branch, New Jersey.
President and Chief Executive Office
Paul Giusti is the President and Chief Executive Officer of the Multiple Myeloma Research Foundation (MMRF), a world-renown cancer-research organization. Prior to the MMRF, Mr. Giusti worked as a Chief Executive Officer, leader, executive and entrepreneur for over 30 years; he has founded, managed and led a variety of businesses. Early in his career, Mr. Giusti worked as an executive for GE where he held a number of management positions with a wide range of responsibilities.Mr. Giusti has worked closely with the MMRF since its founding in 1998. In addition to chairing the successful $100 million capital campaign, he has served as a consultant for a number of foundation projects, led several MMRF outreach efforts and spoken on behalf of the MMRF.Mr. Giusti holds a Bachelor of Science degree from the Colorado School of Mines and an MBA from Harvard University.
Chief Financial Officer
Rob Miani joined the MMRF team as Chief Financial Officer in 2016. Most recently he was the Vice President of Finance and Corporate Controller of Aptuit, LLC, a global contract research organization providing integrated early discovery to mid-phase drug development services in the pharmaceutical industry.Rob has over 20 years of leadership experience in the private and public sectors, holding managerial positons in the renewable energy, private equity, Internet and technology industries, including Davenport Newberry, Oak Investment Partners and INT Media Group. He began his career with Arthur Anderson LLP in the Assurance and Business Advisory Services Division. Rob is a CPA and received his BS degree in Accounting from Fairfield University.
|Daniel Auclair, PhD
Senior Vice President of Research
Dr. Daniel Auclair, who managed the MMRF Multiple Myeloma Genomics Initiative from 2007-2010, has rejoined the company after three years at the Broad Institute of MIT and Harvard.As senior leader in the Cancer Program at the Broad Institute, Dr. Auclair was involved with a wide range of academic and industry collaborations centered around cancer genomics and personalized medicine.Prior to this, he spent a decade in the pharmaceutical industry, most notably at Bayer Healthcare where he led a number of cancer drug discovery efforts.Dr. Auclair has been involved in cancer genomics efforts and drug discovery for more than 20 years. He has been honored as one of the 2017 PharmaVOICE 100. The PharmaVOICE 100 is an annual list of inspirational and innovative individuals recognized for their positive contributions to the life-sciences industry. He has been recognized for his ability to act as a “bridge across the Cancer Archipelago” fostering collaboration in myeloma advancements among academia, government agencies and pharma companies.Dr. Auclair holds graduate and post-graduate degrees in Biochemistry and Nutrition from the University of Montreal and conducted postdoctoral studies at the Dana-Farber Cancer Institute/Harvard Cancer Center.
Vice President of Events
Laura Gilman is the Vice President of Events at the MMRF where she manages the entire events portfolio. Prior to joining the MMRF in 2010 Ms. Gilman was the Vice President of Citigroup’s Investment Research Conferences where she directed the design and execution of the bank’s high profile research conferences and events. Before joining Citigroup, Ms. Gilman was the Director of Meetings, Client Relations and Incentives at Victoria’s Secret Beauty. She began her career at Morgan Stanley managing the bank’s IPO Roadshows. Ms. Gilman has over 20 years of experience designing and executing events and initiatives that generate revenue. She received her B.A. in English Literature from the Catholic University of America and lives in Westport, CT with her husband and son.
Vice President of Business Development
Christopher Williams was named Vice President of Business Development at the MMRF in 2017 responsible for business development, partnership and joint venture efforts for the foundation. He is a business development leader with a strong scientific background, specializing in the pharmaceutical and diagnostics space. Most recently he served as the VP of Business Development at WaveSense where he was in charge of their US commercialization strategy and product expansion, as well as, being responsible for overseeing their strategic partner relationships.Previously Chris was VP of Business Development at SkylineDx providing commercialization strategy for their oncology portfolio. With PerkinElmer, as the Market Segment Leader in Oncology he had responsibility for their cancer diagnostic products including strategy, launch activities, external presentations and marketing execution.While at Millennium Pharmaceuticals Chris held roles in the Protein Science, Technology Development and Proteomics groups. He also had scientific roles at Schering-Plough and the Sandoz Research Institute.Chris holds graduate and post-graduate degrees in Microbiology/Molecular Biology and Protein Biochemistry from Clemson University.
|Anne Quinn Young, MPH
Senior Vice President, Marketing & Communications
Anne Quinn Young, MPH, is Senior Vice President, Marketing & Communications at the MMRF where she leads brand strategy and execution of marketing and communications efforts across channels, as well as oversees the development of educational programming for patients and healthcare professionals to drive patient engagement in the Foundation’s mission. Anne joined the MMRF in 2002 to lead these efforts, but spent the last three years building out the Foundation’s Development department as the Vice President of Development.Prior to joining the MMRF, she was a consultant in the Healthcare Practice of Datamonitor, a global market research and business intelligence company. She previously worked in healthcare public relations at Burson-Marsteller and the Chandler Chicco Agency, following a postgraduate internship at the Department of Justice, Antitrust Division.Anne has a Master of Public Health from the Mailman School of Public Health of Columbia University and graduated cum laude from Dartmouth College with a Bachelor of Arts in Government.
|Karen Dietz, JD, MBA
Corporate Counsel and Secretary
Karen Dietz joined the MMRF as Corporate Counsel and Secretary in 2007. She oversees corporate governance, contract negotiations, compliance, and manages the intellectual property portfolio for the MMRF and its subsidiary companies. In recent years, Karen has focused her efforts on the contracts and compliance for MMRF’s landmark CoMMpassSM Study, the MMRF Prevention Project, the MMRF Immunotherapy Initiative, and the MMRF Answer Fund. Additionally, Karen has concentrated efforts on optimizing the governance structure of the MMRF’s subsidiary company, the Multiple Myeloma Research Consortium, and working with the consortium sites to launch its first innovative platform trial. Karen earned her Doctorate of Jurisprudence and her Masters of Business Administration from Western New England University. Karen earned her Bachelor of Science in Justice and Law Administration from Western Connecticut State University.
Manager, Washington Nationals and Former MLB Player
|James T. Brown
Host, “The NFL Today” on CBS
Host, “Thursday Night Football” on CBS
Special Correspondent, CBS News
NBC and MLBN Broadcaster
Model and Spokesperson
|Clive J. Davis
Chief Creative Officer, Sony Music Entertainment
Grammy Award-Winning Singer, Songwriter and Record Producer
Olympic Figure Skating Champion
Speaker, Author, Commentator
Legendary Football Coach and Analyst, ESPN
Actress, Director, Producer and Writer
|Senator Kay Bailey Hutchison
Former United States Senator, Texas
Olympic Speed Skater
News Anchor, Co-Host, Fourth Hour of “Today”
Pianist and Singer
|Sugar Ray Leonard
Boxing Legend, Entrepreneur and Author
Olympic Figure Skating Champion
Musician, Composer, Educator
Managing and Artistic Director, Jazz at Lincoln Center
Academy Award Winning Actress & Activist
Actor, Producer, and Writer
Inside Edition Anchor and Author
Music Manager and Talk Show Host
Correspondent, HBO’s “Real Sports with Bryant Gumbel”
Weather and Features Reporter
NBC News and The Today Show
Former Major League Baseball Player and Coach
MSNBC Daytime Breaking-News Anchor
Co-Founder and Senior Vice President, Orlando Magic
ABC News Journalist, Anchor
President and Partner
|Lester B. Knight
Founding and Managing Partner
RoundTable Healthcare Partners
|Philip J. Purcell
President & Chief Operation Officer
UBS Investment Bank
Chairman & CEOUBS Group Americas
MemberUBS Group Executive Board
MemberUBS Group Managing Board